



Curriculum Vitae

William David Summers, M.D.
Alabama Clinical Therapeutics, LLC
3528 Vann Road, Suite 101
Birmingham, Alabama 35235

Telephone: (205) 833-2228 **Fax:** (205) 833-6225

Additional Offices:

William D. Summers, MD, LLC
52 Medical Park East Drive, Suite 215
Birmingham, Alabama 35235

Shelby OB/GYN
408 First Street North, Suite 200
Alabaster, AL 35007

Specialties: Gynecology, Urology, Weight Loss

Education:

1986 – 1989	OB-GYN, Residency University of Tennessee – Regional Medical Center Memphis, TN
1985-1986	Urology, Internship VA Hospital Memphis, TN
1985 – 1986	OB-GYN, Internship University of Tennessee – Regional Medical Center Memphis, TN
1981 – 1985	Medical Degree University of Tennessee College of Medicine Memphis, TN
1977 – 1981	Bachelor of Science University of Memphis Memphis, TN

Work Experience:

2006-Present	Investigator Alabama Clinical Therapeutics Birmingham, Alabama
2006-Present	Private Practice-GYN & Weight Loss Clinics 52 Medical Park East Drive, Suite 215 Birmingham, Alabama 35235

Research Experience (continued):


9. "A Long-term, Open Label, Multicenter Study to Evaluate the Safety of XXX Oral Dose of a New Modified-Release III Three Times Daily for up to 5 Days During the Menstrual Cycle in Women with Heavy Menstrual Bleeding Associated with Menorrhagia"
10. A Multi-Center, Placebo Controlled, Safety and Efficacy Study of the Selective Progesterone Receptor Modulator XXX in Anemic, Pre-Menopausal Women with Symptomatic Uterine Fibroids Requiring Hysterectomy"
11. A Phase III Randomized, Double Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Repeated-Dose Study of the Analgesic Efficacy and Safety of XXX Versus Placebo for the Treatment of Postoperative Pain After Abdominal Laparoscopic Surgery
12. "A Phase III, Three-arm, Parallel Design, Placebo-controlled, Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of XXX in the Treatment of Premenopausal Women with Symptomatic Uterine Fibroids"
13. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of XXX Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women
14. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-AND ACTIVE-CONTROLLED EFFICACY AND SAFETY STUDY OF THE EFFECTS OF XXX COMBINATIONS ON ENDOMETRIAL HYPERPLASIA AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
15. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY AND EFFICACY OF XXX FOR THE TREATMENT OF VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
16. Multi-center, open-label, uncontrolled study to investigate the efficacy and safety of the transdermal contraceptive patch containing XXX in a 21 day regimen for 13 cycles in 1050 healthy female subjects
17. A twenty-four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of XXXXXX, with up-titration, 100 milligrams administered orally once daily in naturally postmenopausal women with hypoactive sexual desire disorder in North America
18. A Twenty-Eight Week, Open-Label, Safety, Extension Trial of XXXXXX 100 Milligrams Daily in Premenopausal and Naturally Postmenopausal Women with Hypoactive Sexual Desire Disorder in North America
19. An Open Label Study to Evaluate the Contraceptive Efficacy and Safety of XXXXXX Transdermal Delivery System
20. A Multicenter, Open-Label, Randomized Study of the Contraceptive Efficacy and Safety of xxx Compared to xxx

Research Experience (continued):


21. Evaluate the Efficacy and Safety of XXX in Subjects with Moderate to Severe Endometriosis Associated Pain
22. A Randomized, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of XXX in Women with Anemia Associated with Uterine Leiomyomas
23. Extension Study to Evaluate the Long-Term Safety and Efficacy of XXX in Subjects with Moderate to Severe Endometriosis-Associated Pain
24. A Phase 2b Study to Evaluate the Safety and Efficacy of XXX in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids
25. A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of XXX During 13 Cycles
26. A single-arm, open-label, multicenter Phase 3 study of the contraceptive efficacy and tolerability of the XXX transdermal contraceptive delivery system (TCDS)
27. A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg XXX Administered Orally in the Treatment of Premenopausal Women with Confirmed Symptomatic Uterine Fibroids
28. A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination with XXX for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women
29. A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with XXX in Subjects with Moderate to Severe Endometriosis-Associated Pain
30. Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids
31. A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis
32. A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Clinical Study of XXX for the 26-Week Continuous Treatment of Abnormal Uterine Bleeding in Women with Uterine Fibroids
33. A Phase 3b Study to Evaluate the Long-Term Safety and Efficacy of XXX in Combination with XXX for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Postmenopausal Women
34. A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of XXX for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women

Research Experience (continued):

35. A Randomized, Double-Blind, Placebo-controlled, multiple ascending dose study in subjects with obesity, XXX will be evaluated in approximately 108 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects
36. A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of XXX in Women Suffering from Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause
37. A Randomized, Place-Controlled, Double-Blind Phase 3 Clinical Study to Investigate the Long-Term Safety of XXX in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated with Menopause
38. A Phase 3, Open-label, Multi-center, Single-arm Study to Assess Contraceptive Efficacy and Safety of the XXX Premenopausal Females up to 35 Years of Age
39. Testosterone Replacement therapy for Assessment of long-Term Vascular Events and efficacy ResponSE in hypogonadal Men (XXX) Study
40. 24-hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Treated with XXX Nasal Testosterone Gel (Phase 4 Study)
41. A PHASE IV OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP, THREE TREATMENT ARM, MULTICENTER STUDY ON HYPOGONADAL MALES TO EVALUATE THE EFFECT ON 24-HOUR AMBULATORY BLOOD PRESSURE AFTER 16-WEEK CONTINUOUS TREATMENT WITH MARKETED TESTOSTERONE PRODUCTS
42. A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFECTS OF XXX ON THE OCCURANCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT
43. PROMINENT XXX TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES
44. A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of XXX in the Treatment of Obesity



William David Summers, M.D.



Date